Frederik Marmé

Oct 29, 2024 | emjreviews.com | Peter Schmid |Virginia Kaklamani |Frederik Marmé

The Treatment Landscape for ER+/HER2- Advanced/Metastatic Breast CancerOver 70% of breast cancers are ER+/HER2-, for which the backbone of treatment is ET.1-3 Advanced breast cancer (aBC) can be considered to include both inoperable, locally advanced breast cancer and metastatic breast cancer (mBC). While aBC/mBC remains largely incurable, important advances over the past 20 years have improved overall survival in patients with ER+/HER2- disease.

Jan 25, 2024 | futuremedicine.com | Hope Rugo |Aditya Bardia |Frederik Marmé |Javier Cortés

Link to original article hereLink to original article hereThis is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. AcknowledgmentsThe authors would like to thank the study participants and their caregivers and families for their participation and commitment to clinical research. Thank you to the clinical trial investigators and their team members, without whom this work would not be possible.